Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download The Profit Pill PDF full book. Access full book title The Profit Pill by Amin Jagani. Download full books in PDF and EPUB format.
Author: Amin Jagani Publisher: ISBN: 9781777513610 Category : Languages : en Pages : 126
Book Description
The healthcare and biopharmaceutical sector has long been considered a safe haven due to relatively inelastic demand during times of recession and market downturns. Nowhere is this more evident than during the COVID19 Pandemic when this sector has continued to rally while many other sectors suffered significant corrections. However, the pharma and biotech sector is filled with risks and is not for the faint of heart unless you adopt a tried and true approach to investing in this sector. This book examines the application of the discipline of value investing to pharma and biotech stocks. Value Investing has oscillated between favor and disfavor over the past 100 years based on market psychology. It is a long-term strategy where investors can be handsomely rewarded when their discounted bets revert to the mean. In this book, we explore the strategies used by value investors to evaluate pharmaceutical and biotech stocks and profit handsomely as a result.The principles taught in this book are essentials that will still be true 20 to 30 years from now. You'll learn how to think about pharmaceutical investing so that when a new opportunity comes along, you'll be better equipped to make that calculated bet. This book provides a roadmap to guide investors seeking alpha market-beating returns in the pharmaceutical industry and reap consistent annual returns of 20% - 25% in the long run.
Author: Amin Jagani Publisher: ISBN: 9781777513610 Category : Languages : en Pages : 126
Book Description
The healthcare and biopharmaceutical sector has long been considered a safe haven due to relatively inelastic demand during times of recession and market downturns. Nowhere is this more evident than during the COVID19 Pandemic when this sector has continued to rally while many other sectors suffered significant corrections. However, the pharma and biotech sector is filled with risks and is not for the faint of heart unless you adopt a tried and true approach to investing in this sector. This book examines the application of the discipline of value investing to pharma and biotech stocks. Value Investing has oscillated between favor and disfavor over the past 100 years based on market psychology. It is a long-term strategy where investors can be handsomely rewarded when their discounted bets revert to the mean. In this book, we explore the strategies used by value investors to evaluate pharmaceutical and biotech stocks and profit handsomely as a result.The principles taught in this book are essentials that will still be true 20 to 30 years from now. You'll learn how to think about pharmaceutical investing so that when a new opportunity comes along, you'll be better equipped to make that calculated bet. This book provides a roadmap to guide investors seeking alpha market-beating returns in the pharmaceutical industry and reap consistent annual returns of 20% - 25% in the long run.
Author: Milton M. Silverman Publisher: University of California Press ISBN: 0520368738 Category : Business & Economics Languages : en Pages : 422
Book Description
This title is part of UC Press's Voices Revived program, which commemorates University of California Press’s mission to seek out and cultivate the brightest minds and give them voice, reach, and impact. Drawing on a backlist dating to 1893, Voices Revived makes high-quality, peer-reviewed scholarship accessible once again using print-on-demand technology. This title was originally published in 1974.
Author: Merrill Goozner Publisher: Univ of California Press ISBN: 9780520246706 Category : Business & Economics Languages : en Pages : 308
Book Description
"Goozner shows how drug innovation is driven by dedicated scientists intent on finding cures for diseases, not by pharmaceutical firms, whose bottom line often takes precedence over the advance of medicine. Stories of a university biochemist who spent twenty years searching for single blood protein that later became the best-selling biotech drug in the world, a government employee who discovered the causes for dozens of crippling genetic disorders, and the Department of Energy-funded research that made the Human Genome Project possible - these accounts illustrate how medical breakthroughs actually take place.".
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309468086 Category : Medical Languages : en Pages : 235
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: Dominique A. Tobbell Publisher: Univ of California Press ISBN: 0520271130 Category : Business & Economics Languages : en Pages : 310
Book Description
"Tobbell analyzes the political and economic history of the alignment of the pharmaceutical industry, academic institutions and their faculty and organized medicine. This book is essential reading for policymakers and their staff as well as persons who study the history of health policy and those who contribute to it through medical research, advocacy and journalism. " -Daniel Fox, author of The Convergence of Science and Governance: Research, Health Policy, and American States "Dominique Tobbell’s vivid, balanced and probing account of pharmaceutical politics is a significant, needed analysis of the relationships between the pharmaceutical industry, university researchers, the medical profession and government in the Cold War period. More than this, Pills, Power, and Policy shows why it continues to be difficult to agree in the United States on the relative roles of corporate enterprise, government regulation, technological innovation, freedom to prescribe, and consumer marketing and protection, all played out against the rising costs of health care. Timely and thought-provoking."--Rosemary A. Stevens. DeWitt Wallace Distinguished Scholar, Department of Psychiatry, Weill Cornell Medical College "A superb and compelling account of the creation of one of America’s most reviled entities: Big Pharma. With clarity and subtlety, Pills, Power, and Policy weaves together the political, economic, and the medical to reveal the entangled history behind our modern pharmaceutical predicament."--Andrea Tone, Ph.D., Professor of History & Canada Research Chair in the Social History of Medicine, McGill University “Pills, Power and Policy provides an outstanding description and analysis of the evolution of drug policy. It is an extremely important contribution to our understanding of the political, scientific, and economic nature of pharmaceutical regulation." -Daniel S. Greenberg, Washington journalist and author of Science, Money and Politics: Political Triumph and Ethical Erosion
Author: Marcia Angell Publisher: Random House Trade Paperbacks ISBN: 0375760946 Category : Business & Economics Languages : en Pages : 354
Book Description
During her two decades at The New England Journal of Medicine, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes the shocking truth of what the pharmaceutical industry has become–and argues for essential, long-overdue change. Currently Americans spend a staggering $200 billion each year on prescription drugs. As Dr. Angell powerfully demonstrates, claims that high drug prices are necessary to fund research and development are unfounded: The truth is that drug companies funnel the bulk of their resources into the marketing of products of dubious benefit. Meanwhile, as profits soar, the companies brazenly use their wealth and power to push their agenda through Congress, the FDA, and academic medical centers. Zeroing in on hugely successful drugs like AZT (the first drug to treat HIV/AIDS), Taxol (the best-selling cancer drug in history), and the blockbuster allergy drug Claritin, Dr. Angell demonstrates exactly how new products are brought to market. Drug companies, she shows, routinely rely on publicly funded institutions for their basic research; they rig clinical trials to make their products look better than they are; and they use their legions of lawyers to stretch out government-granted exclusive marketing rights for years. They also flood the market with copycat drugs that cost a lot more than the drugs they mimic but are no more effective. The American pharmaceutical industry needs to be saved, mainly from itself, and Dr. Angell proposes a program of vital reforms, which includes restoring impartiality to clinical research and severing the ties between drug companies and medical education. Written with fierce passion and substantiated with in-depth research, The Truth About the Drug Companies is a searing indictment of an industry that has spun out of control.
Author: Milton M. Silverman Publisher: Univ of California Press ISBN: 0520328906 Category : Business & Economics Languages : en Pages : 422
Book Description
This title is part of UC Press's Voices Revived program, which commemorates University of California Press’s mission to seek out and cultivate the brightest minds and give them voice, reach, and impact. Drawing on a backlist dating to 1893, Voices Revived makes high-quality, peer-reviewed scholarship accessible once again using print-on-demand technology. This title was originally published in 1974.
Author: Steven Brill Publisher: Random House ISBN: 0812996968 Category : History Languages : en Pages : 528
Book Description
NEW YORK TIMES BESTSELLER • A NEW YORK TIMES NOTABLE BOOK • “A tour de force . . . a comprehensive and suitably furious guide to the political landscape of American healthcare . . . persuasive, shocking.”—The New York Times America’s Bitter Pill is Steven Brill’s acclaimed book on how the Affordable Care Act, or Obamacare, was written, how it is being implemented, and, most important, how it is changing—and failing to change—the rampant abuses in the healthcare industry. It’s a fly-on-the-wall account of the titanic fight to pass a 961-page law aimed at fixing America’s largest, most dysfunctional industry. It’s a penetrating chronicle of how the profiteering that Brill first identified in his trailblazing Time magazine cover story continues, despite Obamacare. And it is the first complete, inside account of how President Obama persevered to push through the law, but then failed to deal with the staff incompetence and turf wars that crippled its implementation. But by chance America’s Bitter Pill ends up being much more—because as Brill was completing this book, he had to undergo urgent open-heart surgery. Thus, this also becomes the story of how one patient who thinks he knows everything about healthcare “policy” rethinks it from a hospital gurney—and combines that insight with his brilliant reporting. The result: a surprising new vision of how we can fix American healthcare so that it stops draining the bank accounts of our families and our businesses, and the federal treasury. Praise for America’s Bitter Pill “An energetic, picaresque, narrative explanation of much of what has happened in the last seven years of health policy . . . [Brill] has pulled off something extraordinary.”—The New York Times Book Review “A thunderous indictment of what Brill refers to as the ‘toxicity of our profiteer-dominated healthcare system.’ ”—Los Angeles Times “A sweeping and spirited new book [that] chronicles the surprisingly juicy tale of reform.”—The Daily Beast “One of the most important books of our time.”—Walter Isaacson “Superb . . . Brill has achieved the seemingly impossible—written an exciting book about the American health system.”—The New York Review of Books
Author: J. Douglas Bremner Publisher: Penguin ISBN: 1440630054 Category : Medical Languages : en Pages : 452
Book Description
A medical expert reveals risks of the most commonly prescribed drugs-and why the drug industry doesn't want consumers to know about them. Recent scandals involving diabetes drugs, Vioxx, and many other medications reveal the serious and undisclosed risks of some of the most commonly used prescription drugs in this country. In Before You Take That Pill, Dr. J. Douglas Bremner, a researcher and clinician at Emory University whose study on Accutane and depression made headlines, offers an inside look at the pharmaceutical industry, as well as a scientifically backed assessment of the risks of more than three hundred prescribed medications, vitamins, and supplements. While many drugs are essential to the health of consumers, as Dr. Bremner explains, for many people, the benefits may not outweigh the potential side effects. This book contains warnings that are not on the drug labels. It also exposes tricks of the trade that demonstrate how the profit-making interests of "big pharma" may not always be in line with the safety of the public - from the corruption that exists in the drug approval process to the tactics drug companies use to encourage doctors to prescribe their products. Most important, Before You Take That Pill empowers readers by giving them sound information on specific medications so they can understand and weigh the potential risk themselves. Backed by the latest studies, as well as insight from a doctor who is in the trenches, this book should be on the shelf of every drug consumer.
Author: Amin Jagani
Author: Amin Jagani
Author: Milton M. Silverman
Author: Merrill Goozner
Author: National Academies of Sciences, Engineering, and Medicine
Author: Dominique A. Tobbell
Author: Marcia Angell
Author: Milton M. Silverman
Author: Steven Brill
Author: J. Douglas Bremner
Author: Milton Silverman